You can view or download Celim study biopsy egfr presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)†

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial .

Sign in to explore collection of abstracts, journal articles, posters, videos, and slides. [email protected]

Background: Initially, unresectable colorectal liver metastases can be resected after response to chemotherapy. While cetuximab has been shown to increase response and resection rates, the …

The study started with the protocol version 1.2 (12 April 2012) that included the first amendment that was issued as answer to request during the submission process to the ethics committees and the …

Patients with liver metastasis will be screened for this study. Eligible patients will complete the pretreatment evaluation including an abdominal CT scan that will be presented to the local surgeon …

Survival with cetuximab / FOLFOX or cetuximab / FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study Gunnar Folprecht,

Dec 7, 2012 · Resectability and agreement between surgeons: Review of CT- and MRI- scans of the CELIM study (Multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in …

Nov 1, 2017 · Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)